Hematology

Pages we plan to refresh

• Anemia Diagnostic Flowchart: we plan to update the older reference base and build a clearer pathway around MCV, reticulocyte response, iron studies, B12/folate, hemolysis, kidney disease, inflammation, marrow disease and bleeding.
• Iron Deficiency Anemia / IDA vs Anemia of Chronic Disease: we plan to strengthen ferritin and transferrin-saturation interpretation in inflammatory states and add contemporary context for functional iron deficiency, reticulocyte hemoglobin measures, soluble transferrin receptor and mixed etiologies.
• Iron Deficit Multi-Calc and Iron Dextran tools: we plan to update these beyond older Cosmofer/Infed-centered approaches and incorporate current IV iron products, product-specific maximum doses, infusion requirements, adverse reactions and labeling.
• Oral & Parenteral Iron Products: we plan to update currently marketed preparations, elemental-iron content, oral dosing strategies, absorption interactions, IV formulations and practical selection considerations.
• Elevated INR / Warfarin reversal: the current page relies heavily on older ACCP guidance. We plan to update vitamin K use, bleeding severity, four-factor PCC, plasma, drug interactions, urgent reversal and links to current anticoagulation guidance.
• Warfarin nomograms: we plan to preserve useful institutional examples while clearly separating historical nomograms from contemporary patient-specific initiation, maintenance, peri-procedural and interaction management.
• Heparin dosing: we plan to update VTE/ACS distinctions, obesity, aPTT versus anti-Xa monitoring, renal considerations, protocol customization, bleeding surveillance and HIT evaluation.
• Argatroban / DTI page: we plan to rebuild this as a dedicated direct-thrombin-inhibitor and HIT resource rather than leaving it inside older mixed IV medication material.
• Wells PE / DVT: we plan to retain these validated rules while adding current diagnostic-pathway context, including D-dimer strategies, age adjustment where appropriate, imaging and special-population limitations.
• ANC / neutropenia: we plan to update the background discussion, febrile-neutropenia context, medication causes, growth-factor links and contemporary interpretation of baseline neutrophil variation.
• Colony-Stimulating Factors: we plan to remove obsolete products, update G-CSF/ESA agents and biosimilars, modernize hemoglobin-target language and improve oncology/CKD cross-linking.
• Thrombocytopenia causative list: we plan to update medication causes and add a clearer differential approach for pseudothrombocytopenia, sepsis/DIC, HIT, immune thrombocytopenia, TMA and marrow disease.
• TPO-receptor agonists: the current portal effectively points to eltrombopag alone. We plan to build a class-level reference covering current agents, indications, liver considerations, platelet targets and ITP/aplastic-anemia context.
• G6PD deficiency: we plan to update medication-risk categories, evidence quality, quantitative testing considerations and the limitations of testing during or soon after acute hemolysis.
• Antiplatelets / LMWH / DTIs / thrombolytics: we plan to verify current product availability, renal dosing, indications, reversal strategies, monitoring and contemporary role within cardiovascular and VTE treatment.
• New hematology tools: we plan to evaluate adding dedicated decision-support for HIT (4Ts), TTP/TMA assessment, DIC scoring, reticulocyte production, corrected reticulocyte count and other high-value hematology workflows before adding calculators simply to expand the list.